Kidney International Supplements最新文献

{"title":"Title Page","authors":"","doi":"10.1016/S2157-1716(17)30104-1","DOIUrl":"https://doi.org/10.1016/S2157-1716(17)30104-1","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 2","pages":"Page A5"},"PeriodicalIF":5.5,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(17)30104-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72054763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines, policies, and barriers to kidney care: findings from a global survey","authors":"Meaghan Lunney ,&nbsp;Mona Alrukhaimi ,&nbsp;Gloria E. Ashuntantang ,&nbsp;Aminu K. Bello ,&nbsp;Ezequiel Bellorin-Font ,&nbsp;Mohammed Benghanem Gharbi ,&nbsp;Vivekanand Jha ,&nbsp;David W. Johnson ,&nbsp;Kamyar Kalantar-Zadeh ,&nbsp;Rumeyza Kazancioglu ,&nbsp;Michelle E. Olah ,&nbsp;Timothy Olusegun Olanrewaju ,&nbsp;Mohamed A. Osman ,&nbsp;Yasin Parpia ,&nbsp;Jeffrey Perl ,&nbsp;Harun Ur Rashid ,&nbsp;Ahmed Rateb ,&nbsp;Eric Rondeau ,&nbsp;Laura Sola ,&nbsp;Irma Tchokhonelidze ,&nbsp;Adeera Levin","doi":"10.1016/j.kisu.2017.10.007","DOIUrl":"10.1016/j.kisu.2017.10.007","url":null,"abstract":"<div><p>An international survey led by the International Society of Nephrology in 2016 assessed the current capacity of kidney care worldwide. To better understand how governance and leadership guide kidney care, items pertinent to government priority, advocacy, and guidelines, among others, were examined. Of the 116 responding countries, 36% (<em>n</em> = 42) reported CKD as a government health care priority, which was associated with having an advocacy group (χ2 = 11.57; <em>P</em> = 0.001). Nearly one-half (42%; 49 of 116) of countries reported an advocacy group for CKD, compared with only 19% (21 of 112) for AKI. Over one-half (59%; 68 of 116) of countries had a noncommunicable disease strategy. Similarly, 44% (48 of 109), 55% (57 of 104), and 47% (47 of 101) of countries had a strategy for nondialysis CKD, chronic dialysis, and kidney transplantation, respectively. Nearly one-half (49%; 57 of 116) reported a strategy for AKI. Most countries (79%; 92 of 116) had access to CKD guidelines and just over one-half (53%; 61 of 116) reported guidelines for AKI. Awareness and adoption of guidelines were low among nonnephrologist physicians. Identified barriers to kidney care were factors related to patients, such as knowledge and attitude (91%; 100 of 110), physicians (84%; 92 of 110), and geography (74%; 81 of 110). Specific to renal replacement therapy, patients and geography were similarly identified as a barrier in 78% (90 of 116) and 71% (82 of 116) of countries, respectively, with the addition of nephrologists (72%; 83 of 116) and the health care system (73%; 85 of 116). These findings inform how kidney care is currently governed globally. Ensuring that guidelines are feasible and distributed appropriately is important to enhancing their adoption, particularly in primary care. Furthermore, increasing advocacy and government priority, especially for AKI, may increase awareness and strategies to better guide kidney care.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 2","pages":"Pages 30-40"},"PeriodicalIF":5.5,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials","authors":"Natalia A. Rocha ,&nbsp;Peter A. McCullough","doi":"10.1016/j.kisu.2017.10.004","DOIUrl":"10.1016/j.kisu.2017.10.004","url":null,"abstract":"<div><p>The prevalence of type 2 diabetes is catalyzing a pandemic in kidney disease, with ensuing cardiovascular complications. The effort to identify antidiabetic agents capable of promoting benefits that go beyond the bounds of glucose control has produced remarkable outcomes in recent cardiovascular outcomes trials in patients with type 2 diabetes mellitus, many of whom have diabetic kidney disease. Two novel antidiabetic drug classes, sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), improve cardiovascular outcomes in different ways, with SGLT2is reducing the risk of heart failure and cardiovascular death and GLP-1 RAs being associated with reduced risk of myocardial infarction and cardiovascular death. Further mechanistic studies and additional cardiovascular outcome trials are ongoing and are expected to determine whether these benefits are a result of class effect, as well as to delineate optimum timing for intervention and population target.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Pages 8-17"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel therapies for diabetic kidney disease","authors":"David Z.I. Cherney ,&nbsp;George L. Bakris","doi":"10.1016/j.kisu.2017.10.005","DOIUrl":"10.1016/j.kisu.2017.10.005","url":null,"abstract":"<div><p>Over the past 30 years there have been many complementary therapies developed to achieve glycemic control and have an impact on cardiovascular outcomes, as well as reduce the risk of microvascular disease. The 2 most notable new entries have been the sodium–glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide-1 (GLP-1) agonists. Both these classes of agents have demonstrated reductions in cardiovascular event rates as well as reductions in blood pressure and weight. Moreover, while both have demonstrated a benefit in slowing nephropathy progression, the SGLT2 inhibitors appear to have a significantly greater effect compared with the GLP-1 agents. There is an ongoing trial specifically powered for renal disease progression, CREDENCE (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy). Additionally, there are 2 other classes of agents being tested to slow nephropathy progression, a selective endothelin-1 receptor antagonist, atrasantan, in the SONAR (Study of Diabetic Nephropathy With Atrasentan) trial and a nonsteroidal mineralocorticoid receptor antagonist, finerenone, in the FIDELIO (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus) trial. These and other studies are discussed.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Pages 18-25"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subscription Information","authors":"","doi":"10.1016/S2157-1716(17)30089-8","DOIUrl":"https://doi.org/10.1016/S2157-1716(17)30089-8","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Page A4"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(17)30089-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72052629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S2157-1716(17)30090-4","DOIUrl":"https://doi.org/10.1016/S2157-1716(17)30090-4","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Page A5"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2157-1716(17)30090-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72052630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes","authors":"George L. Bakris","doi":"10.1016/j.kisu.2017.10.002","DOIUrl":"10.1016/j.kisu.2017.10.002","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Page 1"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of diabetic kidney disease: state of the art and future perspective","authors":"Frederik Persson ,&nbsp;Peter Rossing","doi":"10.1016/j.kisu.2017.10.003","DOIUrl":"10.1016/j.kisu.2017.10.003","url":null,"abstract":"<div><p>Approximately 20% to 40% of patients with type 1 or type 2 diabetes mellitus develop diabetic kidney disease. This is a clinical syndrome characterized by persistent albuminuria (&gt; 300 mg/24 h, or &gt; 300 mg/g creatinine), a relentless decline in glomerular filtration rate (GFR), raised arterial blood pressure, and enhanced cardiovascular morbidity and mortality. There is a characteristic histopathology. In classical diabetic nephropathy, the first clinical sign is moderately increased urine albumin excretion (microalbuminuria: 30–300 mg/24 h, or 30–300 mg/g creatinine; albuminuria grade A2). Untreated microalbuminuria will gradually worsen, reaching clinical proteinuria or severely increased albuminuria (albuminuria grade A3) over 5 to 15 years. The GFR then begins to decline, and without treatment, end-stage renal failure is likely to result in 5 to 7 years. Although albuminuria is the first sign of diabetic nephropathy, the first symptom is usually peripheral edema, which occurs at a very late stage. Regular, systematic screening for diabetic kidney disease is needed in order to identify patients at risk of or with presymptomatic diabetic kidney disease. Annual monitoring of urinary albumin-to-creatinine ratio, estimated GFR, and blood pressure is recommended. Several new biomarkers or profiles of biomarkers have been investigated to improve prognostic and diagnostic precision, but none have yet been implemented in routine clinical care. In the future such techniques may pave the way for personalized treatment.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"8 1","pages":"Pages 2-7"},"PeriodicalIF":5.5,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.10.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36890412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New options for the anemia of chronic kidney disease","authors":"Daniel W. Coyne ,&nbsp;David Goldsmith ,&nbsp;Iain C. Macdougall","doi":"10.1016/j.kisu.2017.09.002","DOIUrl":"10.1016/j.kisu.2017.09.002","url":null,"abstract":"<div><p>Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. A series of large trials demonstrated that ESAs have serious safety problems, including increasing cardiovascular and thrombotic events, and death. Analyses suggest high pharmacologic doses of ESAs, rather than the highly achieved hemoglobin, may mediate harm. Hypoxia-inducible factor (HIF) activators stimulate endogenous erythropoietin production and enhance iron availability. In early clinical trials, these oral agents appear to be capable of replacing ESA therapy and minimizing the need for i.v. iron therapy for chronic kidney disease–related anemia, while having other potentially advantageous actions. Large phase 3 trials are underway with several HIF activators. This commentary reviews trends in anemia management, the safety issues related to our present therapies, the role of HIF in regulating erythropoiesis, and the diverse actions of HIF activators.</p></div>","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"7 3","pages":"Pages 157-163"},"PeriodicalIF":5.5,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36935247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing the paradigms for the treatment of chronic kidney disease","authors":"Daniel W. Coyne ,&nbsp;Csaba P. Kovesdy","doi":"10.1016/j.kisu.2017.09.003","DOIUrl":"https://doi.org/10.1016/j.kisu.2017.09.003","url":null,"abstract":"","PeriodicalId":48895,"journal":{"name":"Kidney International Supplements","volume":"7 3","pages":"Pages 155-156"},"PeriodicalIF":5.5,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.kisu.2017.09.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72045014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}